The Discovery of Potent, Selective, and Reversible Inhibitors of the House Dust Mite Peptidase Allergen Der p 1: An Innovative Approach to the Treatment of Allergic Asthma
Citations Over TimeTop 20% of 2014 papers
Abstract
Blocking the bioactivity of allergens is conceptually attractive as a small-molecule therapy for allergic diseases but has not been attempted previously. Group 1 allergens of house dust mites (HDM) are meaningful targets in this quest because they are globally prevalent and clinically important triggers of allergic asthma. Group 1 HDM allergens are cysteine peptidases whose proteolytic activity triggers essential steps in the allergy cascade. Using the HDM allergen Der p 1 as an archetype for structure-based drug discovery, we have identified a series of novel, reversible inhibitors. Potency and selectivity were manipulated by optimizing drug interactions with enzyme binding pockets, while variation of terminal groups conferred the physicochemical and pharmacokinetic attributes required for inhaled delivery. Studies in animals challenged with the gamut of HDM allergens showed an attenuation of allergic responses by targeting just a single component, namely, Der p 1. Our findings suggest that these inhibitors may be used as novel therapies for allergic asthma.
Related Papers
- → European allergen extract units and potency: review of available information(2008)99 cited
- → Mite allergen content in commercial extracts and in bed dust determined by radioallergosorbent tests(1979)17 cited
- The role of mite allergen in chronic urticaria.(1979)
- → Microstop And Greenfirst Treated Home Furnishings: Is It Effective After 24 Months On Mite Allergen Contamination(2010)
- Evaluation of the stability of mite allergen products using ELISA assay(2006)